Shares of Century Therapeutics, Inc. (NASDAQ:IPSC – Get Rating) have earned an average rating of “Buy” from the ten brokerages that are currently covering the firm, Marketbeat Ratings reports. Nine equities research analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $19.00.
A number of research firms recently issued reports on IPSC. EF Hutton Acquisition Co. I reaffirmed a “buy” rating and issued a $16.00 target price on shares of Century Therapeutics in a research note on Monday, April 17th. Bank of America reduced their target price on Century Therapeutics from $23.00 to $20.00 in a research note on Friday, March 17th. Chardan Capital reaffirmed a “buy” rating and issued a $19.00 target price on shares of Century Therapeutics in a research note on Wednesday, March 22nd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $17.00 target price on shares of Century Therapeutics in a research note on Thursday, April 13th.
Insiders Place Their Bets
In other news, insider Luis Borges sold 63,616 shares of the company’s stock in a transaction on Tuesday, March 21st. The stock was sold at an average price of $3.77, for a total transaction of $239,832.32. Following the completion of the sale, the insider now directly owns 43,750 shares in the company, valued at approximately $164,937.50. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 10.30% of the company’s stock.
Institutional Trading of Century Therapeutics
Century Therapeutics Trading Down 1.2 %
NASDAQ IPSC opened at $3.19 on Tuesday. The business’s 50 day moving average is $3.29 and its two-hundred day moving average is $5.35. Century Therapeutics has a 12-month low of $2.81 and a 12-month high of $14.00. The stock has a market capitalization of $190.06 million, a price-to-earnings ratio of -1.48 and a beta of 0.59.
Century Therapeutics (NASDAQ:IPSC – Get Rating) last released its earnings results on Thursday, March 16th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.60) by $0.05. The company had revenue of $0.52 million for the quarter, compared to analysts’ expectations of $2.80 million. Century Therapeutics had a negative return on equity of 39.33% and a negative net margin of 2,127.33%. Equities analysts forecast that Century Therapeutics will post -2.04 earnings per share for the current fiscal year.
About Century Therapeutics
Century Therapeutics, Inc, a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma.
- Get a free copy of the StockNews.com research report on Century Therapeutics (IPSC)
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
- Best Buy’s Comeback Is Still At Play, Earnings Call For Patience
- e.l.f. Beauty Has Giant Quarter, Shares Hit New High
- If You Can Only Pick One Stock For The Rest Of 2023, Pick Nvidia
Receive News & Ratings for Century Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Century Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.